orunmila pharma, inc_presentation
Post on 14-Feb-2017
153 Views
Preview:
TRANSCRIPT
Orunmila Pharma, Inc
First in class HIV-1 derived small peptides that target HSP-70 family member Mortalin and DnaK as therapeutic for cancer, viral replication, inflammation and bacterial infection with little
to no toxicity .
Vincent C. Bond, PhD; CEO and PresidentMing Bo Huang, MD; CRO
Technology: • Mortalin/HSPA9 and DnaK (HSP70) antagonists for the treatment of cancer, inflammation, and
infections.
Issued Patents: • US 8,431,530; US 8,476,237; US 8,551,943; US 8,563,506; US 8,669,226; EP 2440570,
DE602010009528.2.
Patent Applications:• US 13/267,977; US 13/327,244; CA 2,761,121; JP 2012-514976; CN 201080025184.7; HK
12108236.3; IN 8365/CHENP/2011; PCT US2011/055219, and PCT/US11/065137.
Applications:• A dominant and expanding patent position for the composition and use of SMR (& derivatives).• Treatment of cancer, viral infected, and inflammatory cells that over-express mortalin.• Treatment of antibiotic resident bacteria that express DnaK.
Value Proposition:• Demonstrated efficacy i) mortalin-SMR binding; ii) reduction in exosome secretion; iii) induction of
cancer cell, but not “normal” cell death, iv) reduction in HIV particle secretion; and v) bacterial growth inhibition.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
250x103
500x103
750x103
3x106
5x106
8x106
1e+5
1e+6
1e+7
SMRwt peptide in Jurkat SMRmt peptide in Jurkat
SMRwt has no toxic effect on target cellsgrowth.
SummaryNef (Negative Regulatory Factor) is a protein expressed by primate lentiviruses
and a virulence factor able to manipulate host cell machinery. Regions interact with multiple host factors including CXCR4. We identified the SMR as a virus-ended secretion modification region that inhibits an intracellular target HSP 70 family member called mortalin (HSPA9, glucose-regulated protein 75 [GRP75], and peptide-binding protein protein 74 [PBP74]). Mortalin plays an important role in cell proliferation. The SMR peptide, developed by our group, binds with pM affinity to mortalin, and nM affinity to bacteria DnaK acting as an antagonist. It has little toxic effect on target cells. MSM was the first to demonstrate efficacy of HIV-1 derived peptides as therapeutics for cancer, viral replication, inflammation and bacterial infection.
SMRwtSMRmut
top related